Chinese Journal of Pharmacovigilance ›› 2015, Vol. 12 ›› Issue (8): 506-507.
Previous Articles Next Articles
PAN Kun-ming, LIANG Yan, ZHOU Ying, et al
Received:2015-09-02
Revised:2015-09-02
Online:2015-08-08
Published:2015-09-02
CLC Number:
PAN Kun-ming, LIANG Yan, ZHOU Ying, et al. One Case of Pure Red Cell Aplastic Anemia Induced by Isoniazid Combined with Rifapentine[J]. Chinese Journal of Pharmacovigilance, 2015, 12(8): 506-507.
| [1] Fisch P, Handgretinger R, Schaefer H E. Pure Red Cell Aplasia[J]. British Journal of Haematology, 2000, 111(4):1010-1020. [2] Blumer J L, Reed M D. Clinical pharmacology of aminoglycoside antibiotics in pediatrics[J]. Pediatr Clin North Am, 1983, 30(1):195-208. [3] Aouam K, Chaabane A, Loussaief C, et al. Adverse effects of antitub-ercuLar drugs:epidemioLogy, mechanisms, and patient management[J]. Med MaL Infect, 2007,37(5): 253-261. [4] Hoffman R, McPhedran P, Benz E J, et al. Isoniazid-induced pure red ceLL apLasia[J]. Am J Med Sci,1983, 286(1): 2-9. [5] Campbell E A, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase[J]. Cell,2001,104(6):901-912. [6] 陈陵,刘长征. 异烟肼引起纯红细胞再生障碍性贫血1例报告[J]. 实用儿科杂志, 1991, 6(4) :189. [7] Claiborne R A, Dutt A K. Isoniazid-induced pure red cell aplasia[J]. Am Rev Respir Dis, 1985 ,131(6):947-949. [8] 丁国林. 利福平引起再生障碍性贫血一例报告[J].吉林医药,1985,6(4): 57-58. [9] Mariette X, MitjaviLa M T, MouLinie J P, et al. Rifampicin-induced pure red cell aplasia [J]. Am J Med, 1989, 87(4):459-460. [10] Loulergue P, Mir O, Dhote R. Pure red blood cell aplasia and isoniazid use[J]. Emerg Infect Dis, 2007 , 13(9):1427-1428. [11] 黄丹青,张云志,王浩楠,等. 异烟肼致急性再生障碍性贫血1例[J].药物流行病学杂志, 2007, 16(2): 121-122. |
| [1] | SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131. |
| [2] | ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136. |
| [3] | BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140. |
| [4] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
| [5] | LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180. |
| [6] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
| [7] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
| [8] | WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194. |
| [9] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
| [10] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
| [11] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
| [12] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
| [13] | LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212. |
| [14] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
| [15] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
